Abstract:Background: Salidroside (SDS), a phenylpropanoid glycoside, is an antioxidant component isolated from the traditional Chinese medicine Rhodiola rosea and has multifunctional bioactivities, particularly possessing potent hepatoprotective function. Non-alcoholic steatohepatitis (NASH) is one of the most prevalent chronic liver diseases worldwide, but it still lacks efficient drugs. This study aimed to assess the preventive and therapeutic effects of SDS on NASH and its underlying mechanisms in a mouse model subjected to a methionine- and choline-deficient (MCD) diet. Methods: C57BL/6J mice were fed an MCD diet to induce NASH. During or after the formation of the MCD-induced NASH model, SDS (24 mg/kg/day) was supplied as a form of diet for 4 weeks. The histopathological changes were evaluated by H&E staining. Oil Red O staining and Sirius Red staining were used to quantitatively determine the lipid accumulation and collagen fibers in the liver. Serum lipid and liver enzyme levels were measured. The morphology of autophagic vesicles and autophagosomes was observed by transmission electron microscopy (TEM), and qRT-PCR and Western blotting were used to detect autophagy-related factor levels. Immunohistochemistry and TUNEL staining were used to evaluate the apoptosis of liver tissues. Flow cytometry was used to detect the composition of immune cells. ELISA was used to evaluate the expression of serum inflammatory factors. Transcript-proteome sequencing, molecular docking, qRT-PCR, and Western blotting were performed to explore the mechanism and target of SDS in NASH. Results: The oral administration of SDS demonstrated comprehensive efficacy in NASH. SDS showed both promising preventive and therapeutic effects on NASH in vivo. SDS could upregulate autophagy, downregulate apoptosis, rebalance immunity, and alleviate inflammation to exert anti-NASH properties. Finally, the results of transcript-proteome sequencing, molecular docking evaluation, and experimental validation showed that SDS might exert its multiple effects through targeting PPARα. Conclusion: Our findings revealed that SDS could regulate liver autophagy and apoptosis, regulating both innate immunity and adaptive immunity and alleviating inflammation in NASH prevention and therapy via the PPAR pathway, suggesting that SDS could be a potential anti-NASH drug in the future.

Discovery of a INSIG binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting SREBP‐mediated lipogenesis

Discovery of an Insulin-Induced Gene Binding Compound That Ameliorates Nonalcoholic Steatohepatitis by Inhibiting Sterol Regulatory Element-Binding Protein-Mediated Lipogenesis.

Anhydroicaritin Improves Diet-Induced Obesity and Hyperlipidemia and Alleviates Insulin Resistance by Suppressing SREBPs Activation

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

MicroRNA-451 and Genistein Ameliorate Nonalcoholic Steatohepatitis in Mice.

Schisandra Lignans Ameliorate Nonalcoholic Steatohepatitis by Regulating Aberrant Metabolism of Phosphatidylethanolamines

Combinational Applicaton of Silybin and Tangeretin Attenuates the Progression of Non-Alcoholic Steatohepatitis (NASH) in Mice Via Modulating Lipid Metabolism.

Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis

5-Cholesten-3β,25-Diol 3-Sulfate Decreases Lipid Accumulation in Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model

NSC48160 Targets AMPKα to Ameliorate Nonalcoholic Steatohepatitis by Inhibiting Lipogenesis and Mitochondrial Oxidative Stress

Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α

Alisol B Alleviates Hepatocyte Lipid Accumulation and Lipotoxicity via Regulating RARα-PPARγ-CD36 Cascade and Attenuates Non-Alcoholic Steatohepatitis in Mice

Liver lipophagy ameliorates nonalcoholic steatohepatitis through extracellular lipid secretion

Salidroside may target PPARα to exert preventive and therapeutic activities on NASH

Novel hepatoprotective role of Leonurine hydrochloride against experimental non-alcoholic steatohepatitis mediated via AMPK/SREBP1 signaling pathway.

Discovery of N-Aryl- N'-[4-(aryloxy)cyclohexyl]squaramide-Based Inhibitors of LXR/SREBP-1c Signaling Pathway Ameliorating Steatotic Liver Disease: Navigating the Role of SIRT6 Activation

Prevention of Nonalcoholic Hepatic Steatosis by Shenling Baizhu Powder: Involvement of Adiponectin-Induced Inhibition of Hepatic SREBP-1c

Discovery of a natural small-molecule AMP-activated kinase activator that alleviates nonalcoholic steatohepatitis

Mixed Micelles Loaded with the 5-Benzylidenethiazolidine-2,4-dione Derivative SKLB023 for Efficient Treatment of Non-Alcoholic Steatohepatitis

Silibinin Ameliorates Hepatic Lipid Accumulation and Oxidative Stress in Mice with Non-Alcoholic Steatohepatitis by Regulating CFLAR-JNK Pathway

Multiple anti-non-alcoholic steatohepatitis (NASH) efficacies of isopropylidenyl anemosapogenin via farnesoid X receptor activation and TFEB-mediated autophagy